Ann Reynolds has joined the board of directors of Invitrogen, the company said this week.
Until 2002, she was the president of the University of Alabama at Birmingham. Prior to that, she was the chancellor of the City University of New York, and before that, chancellor of the California State University system. Reynolds holds a PhD and a master’s degree in zoology from the University of Iowa, and a bachelor’s degree in biology from Emporia State University in Kansas.
MultiCell Technologies said last week that it has appointed Stephen Chang as president.
Chang is currently the CEO of Astral Therapeutics. He is also president of CURES (Californians United for Research, Economic Development, and Saving Lives), a safe-research advocacy coalition. Chang is also a board member for life sciences organization Biocom. He has served as chief science officer and vice president for Canji/Schering Plough Research Institute from 1998 to 2004. He has also held director-level positions at Chiron and Viagene. Chang earned a PhD in biological chemistry, molecular biology, and biochemistry from the University of California, Irvine.
MultiCell also announced last week that it has appointed Anthony Cataldo as the non-executive co-chairman of the board. Cataldo is currently the chairman of BrandPartners Group. He has also served as executive chairman of Calypte Biomedical, and has been employed by Senetek.
Carl Barrett will become global head of oncology biomarkers at the Novartis Institutes for BioMedical Research in Cambridge, Mass. He used to lead the division of basic sciences and the center for cancer research at the National Cancer Institute.